We also performed a stepwise multiple linear regression analysis to evaluate the impact of Ki-67 proliferative index, HER2 expression, concentration of TILs%, and PD-L1 expression on the outcome of neoadjuvant treatment, represented by the Residual Cancer Burden Score. This evidence concerns the gene ERBB2 and cancer.